"Dasatinib" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
| Descriptor ID |
D000069439
|
| MeSH Number(s) |
D02.886.675.184 D03.383.129.708.198 D03.383.742.148
|
| Concept/Terms |
Dasatinib- Dasatinib
- N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
BMS 354825- BMS 354825
- 354825, BMS
- BMS354825
- BMS-354825
|
Below are MeSH descriptors whose meaning is more general than "Dasatinib".
Below are MeSH descriptors whose meaning is more specific than "Dasatinib".
This graph shows the total number of publications written about "Dasatinib" by people in this website by year, and whether "Dasatinib" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 4 | 1 | 5 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 1 | 3 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 1 | 2 |
| 2025 | 0 | 3 | 3 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dasatinib" by people in Profiles.
-
Nilotinib-Induced Retinal Artery Thrombosis in a Patient With Chronic Myeloid Leukaemia: A Rare Case. Cancer Rep (Hoboken). 2026 Feb; 9(2):e70501.
-
Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway. Cell Rep Med. 2025 Feb 18; 6(2):101941.
-
Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma. Proc Natl Acad Sci U S A. 2025 Jan 28; 122(4):e2319474122.
-
Characterization of Human Senescent Cell Biomarkers for Clinical Trials. Aging Cell. 2025 May; 24(5):e14489.
-
Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling. Int J Cancer. 2024 Nov 15; 155(10):1792-1807.
-
Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med. 2024 Sep; 30(9):2605-2612.
-
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023 Jul; 10(7):e510-e520.
-
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
-
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021 11; 9(11).
-
Epigenetic and senescence markers indicate an accelerated ageing-like state in women with preeclamptic pregnancies. EBioMedicine. 2021 Aug; 70:103536.